Synthetic Biology Startup Acquires AI Platform To Disrupt The Drug Industry
Synthetic biology company AbSci ’s recent acquisition of the artificial intelligence platform, Denovium, could help get novel therapeutics to patients more quickly
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: John Cumbers, Contributor Tags: Manufacturing /manufacturing Business /business Innovation /innovation Healthcare /healthcare Source Type: news